- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CP2CJ/ CYP2C19/ CPCJ monoclonal antibody
Anti-CP2CJ/ CYP2C19/ CPCJ antibody for FACS & in-vivo assay
Go to CYP2C19/CYP2C19 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP2596-Ab-1/ GM-Tg-hg-MP2596-Ab-2 | Anti-Human CYP2C19 monoclonal antibody | Human |
| GM-Tg-rg-MP2596-Ab-1/ GM-Tg-rg-MP2596-Ab-2 | Anti-Rat CYP2C19 monoclonal antibody | Rat |
| GM-Tg-mg-MP2596-Ab-1/ GM-Tg-mg-MP2596-Ab-2 | Anti-Mouse CYP2C19 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP2596-Ab-1/ GM-Tg-cynog-MP2596-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CYP2C19 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP2596-Ab-1/ GM-Tg-felg-MP2596-Ab-2 | Anti-Feline CYP2C19 monoclonal antibody | Feline |
| GM-Tg-cang-MP2596-Ab-1/ GM-Tg-cang-MP2596-Ab-2 | Anti-Canine CYP2C19 monoclonal antibody | Canine |
| GM-Tg-bovg-MP2596-Ab-1/ GM-Tg-bovg-MP2596-Ab-2 | Anti-Bovine CYP2C19 monoclonal antibody | Bovine |
| GM-Tg-equg-MP2596-Ab-1/ GM-Tg-equg-MP2596-Ab-2 | Anti-Equine CYP2C19 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP2596-Ab-1/ GM-Tg-hg-MP2596-Ab-2; GM-Tg-rg-MP2596-Ab-1/ GM-Tg-rg-MP2596-Ab-2; GM-Tg-mg-MP2596-Ab-1/ GM-Tg-mg-MP2596-Ab-2; GM-Tg-cynog-MP2596-Ab-1/ GM-Tg-cynog-MP2596-Ab-2; GM-Tg-felg-MP2596-Ab-1/ GM-Tg-felg-MP2596-Ab-2; GM-Tg-cang-MP2596-Ab-1/ GM-Tg-cang-MP2596-Ab-2; GM-Tg-bovg-MP2596-Ab-1/ GM-Tg-bovg-MP2596-Ab-2; GM-Tg-equg-MP2596-Ab-1/ GM-Tg-equg-MP2596-Ab-2 |
| Products Name | Anti-CYP2C19 monoclonal antibody |
| Format | mab |
| Target Name | CYP2C19 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CYP2C19 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species CP2CJ/ CYP2C19/ CPCJ VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMAP000582 | Human CYP2C19 Adenovirus particle |
| ORF Viral Vector | vGMAP000575 | Human CYP2C19 Adenovirus particle |
| ORF Viral Vector | pGMLV000445 | human CYP2C19 Lentivirus plasmid |
| ORF Viral Vector | pGMAP000575 | Human CYP2C19 Adenovirus plasmid |
| ORF Viral Vector | vGMLV000445 | human CYP2C19 Lentivirus particle |
| ORF Viral Vector | pGMAP000582 | Human CYP2C19 Adenovirus plasmid |
Target information
| Target ID | GM-MP2596 |
| Target Name | CYP2C19 |
| Gene ID | 1557 |
| Gene Symbol and Synonyms | CPCJ,CYP2C,CYP2C19,CYPIIC17,CYPIIC19,P450C2C,P450IIC19 |
| Uniprot Accession | P33261 |
| Uniprot Entry Name | CP2CJ_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | Cancer |
| Gene Ensembl | ENSG00000165841 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: CYP2C19, gene name: CYP2C19, also named as CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
